Samsrita Labs Ltd. 2023 AR2
The report outlines Samsrita Labs Limited's financial and operational performance for the fiscal year 2022-2023. During this period, the company underwent a strategic transition, changing its name from Dr Habeebullah Life Sciences Limited and shifting its focus toward bio-pharma activities, including trading and research in drug discovery. Standalone revenue from operations was recorded at INR 2.16 lakhs, with a net loss of INR 70.57 lakhs, primarily due to writing off certain interest receivables and sundry debtors. The company continues to leverage its associate, Krisani Bio Sciences Private Limited, which holds twelve international patents in drug discovery, to transition molecules into commercial stages.
Company: Samsrita Labs Ltd.
Sector: Healthcare & social services
Country: India
Year: 2023
Type: AR2
Pages: 144
Back to company
Samsrita Labs Ltd.
Annual Report
The report outlines Samsrita Labs Limited's financial and operational performance for the fiscal year 2022-2023. During this period, the company underwent a strategic transition, changing its name from Dr Habeebullah Life Sciences Limited and shifting its focus toward bio-pharma activities, including trading and research in drug discovery. Standalone revenue from operations was recorded at INR 2.16 lakhs, with a net loss of INR 70.57 lakhs, primarily due to writing off certain interest receivables and sundry debtors. The company continues to leverage its associate, Krisani Bio Sciences Private Limited, which holds twelve international patents in drug discovery, to transition molecules into commercial stages.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Apr 1, 2022 - Mar 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees